| Document |
Document Title |
|
WO/2024/102177A1 |
Disclosed herein are methods of treating brain cancer in a subject, such as glioblastoma, comprising administering inhibitors of synaptic signaling to the subject.
|
|
WO/2024/101047A1 |
According to the present invention, a graft rejection reaction is reduced, and extracellular vesicles derived from cells having physiological activity against at least one disease among kidney diseases, peripheral arterial disease (PAD),...
|
|
WO/2024/102675A1 |
Pharmaceutical compositions of anti-TSLP-R antibodies, and uses thereof, are provided herein. The pharmaceutical compositions can comprise for example, an anti-TSLP- R antibody, or antigen-binding fragment thereof, a pharmaceutically acc...
|
|
WO/2024/102744A1 |
A method for promoting sleep quality in a subject is disclosed, involving the administration of an effective amount of a formulation comprising two or more phytoestrogen compounds or their analogues that selectively bind to estrogen rece...
|
|
WO/2024/101937A1 |
The present invention relates to a formulation capable of inhibiting the early release of a specific PRS inhibitor and has the effect of preventing the side effects of nausea or vomiting, which may occur when too much of an active ingred...
|
|
WO/2024/101345A1 |
Provided is an agent containing an RGMa inhibition substance, the agent being for suppressing accumulation of abnormal protein aggregates or for inhibiting uptake of abnormal proteins by nerve cells, particularly for preventing or treati...
|
|
WO/2024/102956A1 |
Conjugates comprising a fibroblast activation protein alpha (FAPα)-targeted ligand, a bifunctional or trifunctional linker, and an imaging or therapeutic agent; compositions comprising the conjugates; and methods of use in the imaging a...
|
|
WO/2024/100396A1 |
An oral lozenge. The oral lozenge comprises from 0.02 to 0.5% w/w chlorhexidine or a salt thereof and from 2 to 80% w/w polyol. The polyol comprises xylitol, erythritol or maltitol.
|
|
WO/2024/101406A1 |
The present invention provides a prophylactic and/or therapeutic agent for non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) or liver cancer, the agent containing a material for inhibiting the expression or f...
|
|
WO/2024/099886A1 |
The present disclosure generally relates to compositions and methods to reduce the biological age and/ or reduce the rate of increase of the biological age of an adult animal. More specifically, the present disclosure relates to administ...
|
|
WO/2024/099951A1 |
The present invention relates to a polypeptide for use as a metal-binder, a protein comprising said polypeptide, a nucleic acid molecule encoding said polypeptide or protein, an expression vector comprising the nucleic acid molecule, a r...
|
|
WO/2024/101336A1 |
One embodiment of the present invention provides a compound, or a pharmaceutically acceptable salt thereof, capable of suppressing the splicing anomalies that are a factor in the onset or progression of disease. This disclosure relates t...
|
|
WO/2024/100756A1 |
[Problem] To provide a novel agent for preventing and/or treating inflammation in the uterus, fallopian tubes, and ovaries. [Solution] An agent for preventing and/or treating inflammation in the uterus, fallopian tubes, and ovaries that ...
|
|
WO/2024/100919A1 |
Provided is a novel agent which can induce an effect of inhibiting the expression of a pruritus-related gene and is mainly applicable to human skin or the like. The agent for use in the prevention of pruritus according to the present d...
|
|
WO/2024/101402A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing, for example, a cell proliferative disease, the pharmaceutical composition containing as an active ingredient a cyclic compound that selectively inhi...
|
|
WO/2024/102458A1 |
The present disclosure relates to the administration of trazodone or a pharmaceutically acceptable salt thereof to reverse the pharmacological effects of a 5-HT2A receptor agonist in a subject.
|
|
WO/2024/099320A1 |
A hybrid protein containing a CFH functional unit and a DAF functional unit, and a mutant thereof, an encoding nucleic acid thereof, and a method and the use thereof for treating diseases or conditions related to a complement system; and...
|
|
WO/2024/101440A1 |
Provided is a compound represented by formula (1): [in the formula, the definitions for variables are as defined in the description] or a pharmaceutically acceptable salt thereof.
|
|
WO/2024/096818A1 |
The present disclosure relates generally to compositions for enhancing mental wellbeing, particularly compositions from plant extracts for use in calming energizing or enhancing happiness or euphoria in individuals. Methods disclosed inc...
|
|
WO/2024/096133A1 |
The present invention provides a cell-to-cell human T-lymphotropic virus type 1 (HTLV-1) infection inhibitor that contains a substance that inhibits interaction between N-acetyllactosamine (LacNAc) and galectin-3 (Gal-3).
|
|
WO/2024/096418A1 |
The present invention relates to a pharmaceutical or cosmetics composition having anti-inflammatory, anti-pruritic, anti-allergenic, and deodorant effect, the composition comprising composite extract of Lagerstroemia indica and Persicari...
|
|
WO/2024/095992A1 |
The present invention addresses the problem of providing a novel means for suppressing renal hypofunction, the means being capable of fundamentally improving diseases associated with renal hypofunction, including chronic kidney disease (...
|
|
WO/2024/096124A1 |
The present disclosure provides a microorganism that inhibits oligomer formation of sgA. More specifically, the present disclosure provides a microorganism wherein at least one gene among the curli pili operon gene group, sigma factor ge...
|
|
WO/2024/097571A1 |
Disclosed are compositions and methods for using heme and at least one PAMP and/or DAMP molecule for activating NLRP12 and/or NLRC5 and inflammatory cell death. Also provided is a screening assay for identifying NLRP12 and/or NLRC5 inhib...
|
|
WO/2024/094098A1 |
Provided in the present application are a compound for a delivery system and the use thereof, and an ionizable lipid having a hydrogen bond providing group.
|
|
WO/2024/095793A1 |
[Problem] To provide an antioxidant cosmetic. [Solution] Provided is an antioxidant cosmetic containing at least one component selected from the group consisting of (A) a cyclic carboxamide derivative having a specific structure or a sal...
|
|
WO/2024/095158A1 |
Disclosed are uses of an orexin type 2 receptor (OX2R) agonist at non-awakening concentrations. Also disclosed are compositions and methods for administering an OX2R agonist to a subject (e.g., mammal) in need thereof at a dose that prov...
|
|
WO/2024/096121A1 |
The present disclosure provides a bacterial preparation that can be used to treat inflammatory bowel disease. More specifically, the present disclosure relates to a microorganism in which a gene from at least one of a fimbria operon gene...
|
|
WO/2024/097131A1 |
The present disclosure provides a clinically applicable method to re-balance production of hematopoietic cells in a mammal, including without limitation an aged mammal, by selective depletion of myeloid-biased hematopoietic stem cells (m...
|
|
WO/2024/096014A1 |
The purpose of the present invention is to provide a novel TRPA1 agonist. The present invention relates to a composition for activating TRPA1, comprising a mushroom extract or lenthionine. The composition can enhance appetite and food ...
|
|
WO/2024/096122A1 |
The present disclosure provides a microbiome for the purpose of improving the response rate of an immune checkpoint inhibitor. Specifically, the present disclosure provides a microorganism wherein at least one gene among a flagella-formi...
|
|
WO/2024/096516A1 |
The present invention relates to a composition for transpulmonary delivery of nucleic acid drugs and a use thereof. The composition for transpulmonary delivery of the present invention is specific to lung tissue and specific cells thereo...
|
|
WO/2024/090941A1 |
The present invention relates to a composition for the prevention, amelioration or treatment of an anterior segment eye disease, the composition comprising a plant extract of the genus Aloe as an active ingredient. When the Aloe vera ext...
|
|
WO/2024/090549A1 |
Provided is an agent for preventing or ameliorating neuropathy caused by decreased nerve function due to nerve damage or diabetic neuropathy. The agent for preventing or ameliorating neuropathy is obtained by combining one or more lact...
|
|
WO/2024/090341A1 |
The purpose of the present invention is to provide an anti-aging agent which exhibits an excellent effect such as a mitochondria activating effect. The anti-aging agent according to the present invention is characterized by containing an...
|
|
WO/2024/091932A1 |
The present disclosure provides methods of preventing, lessening the effects, or treating sepsis comprising administering a prophylactically effective amount of defibrotide to a subject in need thereof.
|
|
WO/2024/090329A1 |
The present inventors have found that a pyridoxal synthetic enzyme Pyridoxamine-5'-phosphate oxidase (PNPO) acts as an oxygen sensing mechanism for a novel pathway that is independent from an HIF pathway in chronic hypoxia. A pharmaceuti...
|
|
WO/2024/091451A1 |
Disclosed herein are compositions and methods useful for the treatment or amelioration of various diseases, disorders, or conditions. Some aspects pertain to a pharmaceutical composition comprising 17-ethynyl-10R, 13S-dimethyl 2, 3, 4, 7...
|
|
WO/2024/092166A1 |
A method and composition for enhancing adenosine monophosphate-activated protein kinase (AMPK) activity and improving mitochondrial-related oxidative metabolic parameters in both exercising and sedentary mammals through oral ingestion of...
|
|
WO/2024/091036A1 |
The present invention relates to a composition for treatment of mitochondrial transplantation for immunomodulation and fibrosis control in multiple sclerosis. The present invention confirmed that, when muscle-derived mitochondria are tra...
|
|
WO/2024/090589A1 |
The present invention provides a composition for preventing finger sucking, the composition being applicable to nails and comprising denatonium benzoate and sorbitol. According to the present invention, the bitter taste of the compositio...
|
|
WO/2024/089454A1 |
The present invention relates to a composition, preferably a nutraceutical composition, for use in a method of treatment of post viral infection caused by the virus strain called SARS-CoV-2, or alternatively COVID- 19, chronic fatigue/fa...
|
|
WO/2024/090521A1 |
Provided is a pharmaceutical composition for treating and/or preventing renal cystic ciliopathy, the composition containing a retinoic acid receptor (RAR) agonist.
|
|
WO/2024/087834A1 |
The present invention relates to a composition comprising a growth hormone fusion protein and a use thereof. The composition comprises: the growth hormone fusion protein and at least one of a buffering agent and a protective agent; a use...
|
|
WO/2024/090800A1 |
A lipocalin 2 Inhibitor of the present invention can exhibit the effects of preventing and treating liver fibrosis by inhibiting the induction of liver cells into hepatic stellate cells through the inhibition of lipocalin 2 expression, a...
|
|
WO/2024/090548A1 |
Provided are novel composite materials which contain hydroxyapatite particles and which make it possible to more effectively utilize the activity of the hydroxyapatite particles. An embodiment of the present invention is a hydroxyapatite...
|
|
WO/2024/091007A1 |
The present invention relates to a novel compound and a pharmaceutical composition including same as an active ingredient for the prevention or treatment of pulmonary fibrosis. Specifically, the present invention relates to a compound re...
|
|
WO/2024/091484A1 |
Disclosed are synthetic amniotic fluid compositions comprising ulin-A- statin/urinary trypsin inhibitor (UTI) and ascorbic acid and methods of using the disclosed synthetic amniotic fluid compositions, which may be useful for a variety o...
|
|
WO/2024/084070A1 |
The present invention concerns screening methods to identify compounds that regulate the activity of Acinetobacter baumannii SpoT enzyme, in particular compounds that are able to partially or completely inhibit the hydrolase activity of ...
|
|
WO/2024/085143A1 |
The purpose of the present invention is to provide a novel peptide that could be used to induce an immune response to SARS-CoV-2. A nucleocapsid-derived antigen peptide according to the present disclosure includes the following polypep...
|
